Index -
P/E 36.36
EPS (ttm) 0.65
Insider Own 2.76%
Shs Outstand 302.79M
Perf Week 4.62%
Market Cap 6.94B
Forward P/E 14.96
EPS next Y 1.57
Insider Trans -0.19%
Shs Float 286.65M
Perf Month -0.34%
Income 207.76M
PEG 1.91
EPS next Q 0.23
Inst Own 89.52%
Short Float 3.01%
Perf Quarter 6.52%
Sales 1.83B
P/S 3.79
EPS this Y 91.83%
Inst Trans -1.96%
Short Ratio 3.83
Perf Half Y 19.99%
Book/sh 7.48
P/B 3.15
EPS next Y 26.11%
ROA 6.85%
Short Interest 8.62M
Perf Year 24.83%
Cash/sh 3.38
P/C 6.97
EPS next 5Y 19.00%
ROE 8.74%
52W Range 18.08 - 24.34
Perf YTD -1.92%
Dividend Est. -
P/FCF 23.69
EPS past 5Y -21.77%
ROI 8.47%
52W High -3.33%
Beta 0.57
Dividend TTM -
Quick Ratio 3.30
Sales past 5Y 17.31%
Gross Margin 96.04%
52W Low 30.14%
ATR (14) 0.53
Dividend Ex-Date -
Current Ratio 3.34
EPS Y/Y TTM 15.07%
Oper. Margin 9.34%
RSI (14) 56.83
Volatility 2.10% 2.34%
Employees 1310
Debt/Eq 0.10
Sales Y/Y TTM 13.60%
Profit Margin 11.35%
Recom 1.73
Target Price 26.73
Option/Short Yes / Yes
LT Debt/Eq 0.08
EPS Q/Q 392.82%
Payout 0.00%
Rel Volume 0.64
Prev Close 23.71
Sales Surprise -0.14%
EPS Surprise 17.54%
Sales Q/Q 13.15%
Earnings Apr 30 AMC
Avg Volume 2.25M
Price 23.53
SMA20 1.33%
SMA50 4.11%
SMA200 7.83%
Trades
Volume 1,429,751
Change -0.76%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-11-24 Downgrade
Barclays
Overweight → Equal Weight
$25
Dec-19-23 Initiated
BTIG Research
Buy
$27
Dec-15-23 Initiated
Citigroup
Buy
$31
Sep-26-23 Initiated
H.C. Wainwright
Buy
$28
Aug-22-23 Reiterated
Oppenheimer
Outperform
$25 → $29
Aug-08-23 Initiated
SVB Securities
Market Perform
$18
Jul-11-23 Resumed
Morgan Stanley
Equal-Weight
$21
May-10-23 Resumed
Piper Sandler
Overweight
$28
Mar-09-23 Initiated
Wells Fargo
Overweight
$23
Jan-26-23 Initiated
Credit Suisse
Outperform
$29
Oct-18-22 Initiated
JMP Securities
Mkt Outperform
$26
Jun-24-22 Initiated
BMO Capital Markets
Outperform
$28
Nov-19-21 Initiated
Piper Sandler
Overweight
$34
Nov-03-21 Resumed
Jefferies
Buy
$28
Oct-07-21 Initiated
Jefferies
Buy
$28
Aug-06-21 Reiterated
H.C. Wainwright
Buy
$35 → $64
Jun-15-21 Initiated
H.C. Wainwright
Buy
$47
May-18-21 Resumed
Goldman
Sell
$23
Mar-31-21 Initiated
Credit Suisse
Outperform
$30
Mar-12-21 Initiated
Wolfe Research
Outperform
$35
Show Previous Ratings
Apr-16-24 04:05PM
Mar-28-24 08:13AM
Mar-23-24 05:06AM
Mar-17-24 08:50AM
Mar-08-24 09:38AM
08:15AM
Loading…
08:15AM
Mar-07-24 11:31AM
10:08AM
Mar-06-24 04:45PM
Mar-04-24 07:06PM
Mar-02-24 05:06AM
Feb-27-24 04:05PM
08:00AM
Feb-26-24 07:42AM
Feb-23-24 01:11PM
08:00AM
Loading…
Feb-19-24 08:00AM
Feb-14-24 08:30AM
01:47AM
Feb-13-24 08:00AM
Feb-12-24 09:35AM
Feb-10-24 05:06AM
Feb-09-24 09:35AM
Feb-08-24 06:50PM
09:35AM
Feb-07-24 07:01PM
(Morningstar Research) -7.56%
01:13PM
10:47AM
09:45AM
(Thomson Reuters StreetEvents)
Feb-06-24 08:45PM
06:30PM
05:25PM
Loading…
05:25PM
05:01PM
04:33PM
(Associated Press Finance)
04:05PM
Feb-01-24 04:05PM
Jan-30-24 10:00AM
Jan-29-24 09:40AM
Jan-25-24 08:00AM
Jan-23-24 04:05PM
Jan-22-24 05:00PM
Jan-21-24 01:16PM
Jan-19-24 11:21AM
Jan-18-24 04:05PM
04:00PM
Jan-17-24 11:29AM
Jan-11-24 09:40AM
Jan-08-24 04:40PM
(Investor's Business Daily)
12:43PM
06:12AM
Jan-07-24 04:00PM
Jan-02-24 04:05PM
Dec-19-23 10:16AM
Dec-12-23 08:54AM
Dec-07-23 04:05PM
Dec-05-23 01:51PM
Dec-04-23 07:26PM
08:02AM
08:00AM
Dec-01-23 11:32AM
Nov-29-23 10:45AM
Nov-21-23 04:05PM
Nov-17-23 01:33PM
Nov-10-23 09:00AM
Nov-09-23 04:43PM
Nov-08-23 05:24PM
05:19AM
Nov-06-23 09:47AM
Nov-03-23 12:11PM
Nov-02-23 11:23AM
12:30AM
Nov-01-23 07:00PM
06:05PM
04:05PM
Oct-30-23 10:00AM
Oct-28-23 05:06AM
Oct-27-23 04:58AM
Oct-26-23 10:02AM
Oct-25-23 10:01AM
08:30AM
Oct-22-23 02:30AM
Oct-19-23 06:51PM
08:15AM
Oct-18-23 04:05PM
08:30AM
Oct-12-23 11:40AM
Oct-09-23 02:03AM
Oct-02-23 09:49AM
Sep-20-23 02:15PM
Sep-18-23 09:16AM
Sep-16-23 05:06AM
Sep-15-23 10:23AM
Sep-13-23 11:23AM
08:29AM
Sep-12-23 08:00AM
Sep-11-23 12:31PM
Sep-08-23 11:30AM
Sep-07-23 08:43AM
Sep-06-23 09:33AM
Sep-05-23 11:40AM
09:40AM
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Garber Alan M Director Mar 21 '24 Option Exercise 19.57 23,491 459,719 54,908 Mar 25 07:31 PM Garber Alan M Director Mar 21 '24 Sale 24.01 19,205 461,112 35,703 Mar 25 07:31 PM Haley Patrick J. EVP, Commercial Feb 23 '24 Sale 21.45 47,020 1,008,579 384,866 Feb 27 06:58 PM JOHNSON DAVID EDWARD Director Feb 21 '24 Buy 20.70 190,000 3,932,734 1,100,730 Feb 22 05:08 PM Haley Patrick J. EVP, Commercial Dec 14 '23 Option Exercise 16.29 50,000 814,500 357,687 Dec 14 07:56 PM Haley Patrick J. EVP, Commercial Dec 14 '23 Sale 23.35 50,000 1,167,500 307,687 Dec 14 07:56 PM Hessekiel Jeffrey EVP, General Counsel & Sec Dec 13 '23 Sale 23.01 25,000 575,250 533,345 Dec 14 07:55 PM Haley Patrick J. EVP, Commercial Dec 12 '23 Sale 22.50 14,149 318,352 307,687 Dec 14 07:56 PM Hessekiel Jeffrey EVP, General Counsel & Sec Dec 04 '23 Sale 22.06 25,000 551,500 558,345 Dec 04 06:22 PM Hessekiel Jeffrey EVP, General Counsel & Sec Nov 30 '23 Sale 22.01 25,000 550,250 583,345 Dec 04 06:22 PM JOHNSON DAVID EDWARD Director Nov 27 '23 Buy 21.61 120,409 2,602,038 910,730 Nov 29 04:30 PM JOHNSON DAVID EDWARD Director Nov 27 '23 Sale 21.61 120,409 2,602,038 790,321 Nov 29 04:30 PM Aftab Dana CSO/EVP Disc & Trans Research Aug 30 '23 Sale 22.47 4,600 103,362 399,943 Sep 01 08:15 PM MORRISSEY MICHAEL President and CEO Aug 28 '23 Option Exercise 15.31 360,000 5,511,600 945,496 Aug 30 09:48 PM Senner Christopher J. EVP and CFO Aug 04 '23 Option Exercise 14.74 60,000 884,400 631,631 Aug 07 09:20 PM Senner Christopher J. EVP and CFO Aug 04 '23 Sale 20.68 60,000 1,240,800 571,631 Aug 07 09:20 PM Senner Christopher J. EVP and CFO Aug 03 '23 Option Exercise 14.74 60,000 884,400 631,631 Aug 07 09:20 PM Senner Christopher J. EVP and CFO Aug 03 '23 Sale 20.51 60,000 1,230,600 571,631 Aug 07 09:20 PM Haley Patrick J. EVP, Commercial Aug 03 '23 Sale 20.67 30,553 631,531 285,467 Aug 07 08:24 PM Hessekiel Jeffrey EVP, General Counsel & Sec Aug 01 '23 Option Exercise 14.74 55,710 821,165 627,686 Aug 03 08:02 PM Hessekiel Jeffrey EVP, General Counsel & Sec Aug 01 '23 Sale 19.63 55,710 1,093,587 571,976 Aug 03 08:02 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite